The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease

Condition:   Dry Eye Disease Interventions:   Drug: Topical spironolactone ophthalmic solution, 0.005 mg/cc;   Drug: Placebo Sponsor:   Richard W Yee, MD Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials